FDA inspection
NasPress Pharmaceutical Co., Ltd.: FDA inspection ending Aug 17, 2018
FDA inspection 1064505 · Official Action Indicated (OAI) · Hangzhou
Key facts
| Inspection ID | 1064505 |
|---|---|
| Firm | NasPress Pharmaceutical Co., Ltd. |
| FEI number | 3014268567 |
| Address | No. 1 Haizheng Road, Fuyang District |
| City | Hangzhou |
| Fiscal year | 2018 |
| Inspection end date | Aug 17, 2018 |
| Classification | Official Action Indicated (OAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data